Jan 12, 2026 04:04AM Leerink Partners Reiterates Outperform Rating on Veracyte, Inc (VCYT)

Nov 5, 2025 05:46AM Veracyte, Inc (VCYT) PT Raised to $44 at Needham

Nov 5, 2025 01:59AM Veracyte, Inc (VCYT) PT Raised to $43 at Canaccord Genuity

Nov 4, 2025 04:21PM Veracyte (VCYT) Tops Q3 EPS by 19c, provides guidance

Oct 20, 2025 05:11AM Canaccord Genuity Starts Veracyte, Inc (VCYT) at Hold

Oct 16, 2025 04:09PM Freedom Capital Markets Starts Veracyte, Inc (VCYT) at Buy, PT $45

Sep 29, 2025 04:36AM Veracyte biomarker predicts hormone therapy benefit in prostate cancer

Sep 24, 2025 09:03AM Veracyte to present prostate cancer biomarker data at ASTRO 2025

Aug 27, 2025 11:25AM Veracyte study shows Decipher test predicts chemotherapy benefit

Aug 26, 2025 08:35AM Veracyte completes enrollment for lung cancer test clinical trial

Aug 8, 2025 02:49PM Veracyte, Inc (VCYT) PT Lowered to $28 at Morgan Stanley

Aug 7, 2025 05:36AM William Blair Reiterates Outperform Rating on Veracyte, Inc (VCYT)

Aug 6, 2025 04:12PM Veracyte (VCYT) Tops Q2 EPS by 33c, provides guidance

Jul 24, 2025 05:20PM Veracyte (VCYT) added to S&P 600

May 21, 2025 12:48PM Scotiabank Reiterates Sector Outperform Rating on Veracyte, Inc (VCYT)

May 8, 2025 06:13AM Veracyte, Inc (VCYT) PT Lowered to $41 at Needham

May 7, 2025 04:15PM Veracyte (VCYT) Tops Q1 EPS by 29c, reiterating guidance

Apr 25, 2025 07:00AM Veracyte (VCYT) Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Apr 21, 2025 04:07PM Veracyte (VCYT) Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release

Apr 9, 2025 07:20AM Veracyte, Inc (VCYT) PT Lowered to $37 at Guggenheim

Mar 20, 2025 09:44AM Craig-Hallum Starts Veracyte, Inc (VCYT) at Buy

Feb 25, 2025 06:11AM Needham Reiterates Buy Rating on Veracyte, Inc (VCYT)

Feb 24, 2025 04:10PM Veracyte (VCYT) Tops Q4 EPS by 26c, provides guidance

Jan 29, 2025 07:58AM Veracyte, Inc (VCYT) PT Raised to $51 at Needham

Dec 9, 2024 05:55AM Veracyte (VCYT) spreaders active in December and January 50 calls

Dec 5, 2024 04:15AM Goldman Sachs Downgrades Veracyte, Inc (VCYT) to Neutral

Nov 15, 2024 06:02AM Wolfe Research Starts Veracyte, Inc (VCYT) at Outperform

Nov 7, 2024 07:39AM Veracyte, Inc (VCYT) PT Raised to $44 at Needham

Nov 6, 2024 04:15PM Veracyte (VCYT) Tops Q3 EPS by 30c, provides guidance

Oct 16, 2024 03:51AM UBS Starts Veracyte, Inc (VCYT) at Buy

Sep 30, 2024 07:34AM Veracyte, Inc (VCYT) PT Raised to $40 at Scotiabank

Sep 4, 2024 04:05PM Veracyte (VCYT) Appoints Brent Shafer and Tom Miller to its Board

Aug 28, 2024 05:43AM Veracyte, Inc (VCYT) PT Raised to $37 at Needham

Aug 7, 2024 07:40AM Veracyte, Inc (VCYT) PT Raised to $31 at Needham

Aug 6, 2024 04:20PM Veracyte (VCYT) Tops Q2 EPS by 8c, Beats on Revenue; Offers FY24 Revenue Guidance